Healthcare - Biotechnology - NASDAQ - US
$ 22.92
-14.7 %
$ 1.62 B
Market Cap
-7.99
P/E
CASH FLOW STATEMENT
-81.4 M
OPERATING CASH FLOW
68.3 M
INVESTING CASH FLOW
3.22 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Nurix Therapeutics, Inc.
| Net Income | -144 M |
| Depreciation & Amortization | 13.7 M |
| Capital Expenditures | -8.4 M |
| Stock-Based Compensation | 33.7 M |
| Change in Working Capital | 20.1 M |
| Others | 13.6 M |
| Free Cash Flow | -89.8 M |
Cash Flow
Millions
| Nov-2023 | Nov-2022 | Nov-2021 | Nov-2020 | Nov-2019 | Nov-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (143.9) | (180.4) | (117.2) | (43.2) | (21.7) | (9.4) |
| Depreciation & Amortization | 13.7 | 10.8 | 6.1 | 2.2 | 2.4 | 3.0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 | (0.4) |
| Stock Based Compensation | 33.7 | 28.1 | 15.8 | 4.3 | 0.5 | 0.4 |
| Other Operating Activities | (4.9) | 0.6 | 1.8 | 0.3 | (0.1) | 6 K |
| Change in Working Capital | 20.1 | (19.0) | 9.1 | 36.4 | 19.5 | (25.3) |
| Cash From Operations | (81.4) | (159.8) | (84.4) | 80 K | 0.6 | (31.7) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (8.4) | (12.2) | (5.7) | (4.6) | (1.7) | (1.6) |
| Other Items | 76.7 | 39.4 | (102.6) | (249.9) | 10.1 | 41.6 |
| Cash From Investing Activities | 68.3 | 27.2 | (108.3) | (254.4) | 8.5 | 40.0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 16 K | 2 K |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.2 | 97.8 | 3.7 | 120.9 | 0.1 | 0.5 |
| Cash From Financing Activities | 3.2 | 117.2 | 153.9 | 339.0 | 0.1 | 0.5 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | (9.8) | (15.4) | (38.7) | 84.5 | 9.2 | 8.8 |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (89.8) | (172.1) | (90.0) | (4.6) | (1.1) | (33.3) |